Vaccination against canine herpesvirosis and vaccines therefor
AssigneeMerial Limited
InventorHever Poulet
Life of this patent
Estimating the term…
Abstract
Use of a CHV antigen for the preparation of a vaccine against canine herpesvirosis, which is intended to be administered to gestating bitches as close as possible to whelping, preferably during the final third of gestation, and which produces a high level of anti-CHV antibodies in gestating bitches at the time of whelping, inducing protection in the puppies by transfer of antibodies during suckling. Inactivated anti-CHV vaccine or subunit vaccines, which can be used for vaccinating gestating bitches to protect the puppies by transfer of antibodies.
Claims52
A method for vaccinating puppies against canine herpesvirosis, which comprises administering a vaccine against CHV to a gestating bitch 1 to 20 days, in particular 1 to 15 days, more particularly 5 to 15 days, preferably 5 to 10 days before the presumed date of whelping, typically about 10 days before, and so producing a high level of anti-CHV antibodies in the gestating bitch at the time of whelping, inducing protection in the puppies by transfer of antibodies during suckling.
A method for vaccinating puppies against canine herpesvirosis, which comprises administering a vaccine against CHV to a gestating bitch as close as possible to whelping, preferably during the final third of gestation, and which produces a high level of anti-CHV antibodies in the gestating bitch at the time of whelping, which level is greater than or equal to 0.9 log10, preferably greater than or equal to 1.2 log10, inducing protection in the puppies by transfer of antibodies during suckling.
The method according to claim l, wherein the vaccine is formulated in the form of an oil-in-water emulsion or in the form of a suspension with carbomer.
An anti-CHV vaccine comprising extraction CHV subunits, in a veterinarially acceptable vehicle or excipient.
An anti-CHV vaccine comprising an antigen chosen among the group consisting of inactivated CHV and extraction CHV subunits, in lyophilized form
An anti-CHV vaccine comprising inactivated CHV in an amount which equates to a titer before inactivation of about 105 to about 109.5 TCID50, in particular from 105 to 109 TCID50, preferably from about 106 to about 108 TCID50 per dose, and a veterinarily acceptable vehicle or excipient.
A multivalent vaccine which comprises inactivated CHV vaccine or extractive CHV vaccine and an other canine pathogen vaccine.
Multivalent vaccine pack comprising, separately packaged, a CHV vaccine and a vaccine against another canine pathogen.
Dependencies are inferred from the claim text.